Introduction
Patients and methods
Surgery and post-surgical management
Informed consent
Statistics
Results
Control | TissuGlu®
|
p value | |||
---|---|---|---|---|---|
Total | % | Total | % | ||
n
| 173 | 32 | |||
Age (years) | 62 (±14) | 67 (±13) | 0.094 | ||
BMI | 27 (±7) | 26 (±7) | 0.889 | ||
Previous chemotherapy | 44 | 25.4 | 4 | 12.5 | 0.174 |
Radiation | 30 | 17.3 | 5 | 15.6 | 0.807 |
Nicotine | 24 | 13.9 | 0 | 0.007 | |
Superficial post-surgical hematoma | 29 | 16.8 | 1 | 3.1 | 0.045 |
Post-surgical pain (1–10) | 1.5 (±1) | 2,7 (±0, 8) | 0.787 | ||
Day of drain removal | 4.2 (±1.8) | 3,5 (±1, 5) | 0.008 | ||
Total volume | 191 (±160) | 152 (±116) | 0.08 | ||
Follow-up seroma | 27 | 15.6 | 8 | 27.6 | 0.06 |
Adverse events (revision/infection) | 12 | 6.9 | 0 | 0.22 |
Distribution (% of total) | Adverse event (% of total) | Seroma (% of total) | |
---|---|---|---|
Control | |||
Mastectomy | 63 (36 %) | 5 (38 %) | 13 (48 %) |
Axilla | 79 (46 %) | 4 (31 %) | 12 (44 %) |
SNL | 31 (18 %) | 4 (31 %) | 2 (7 %) |
Total | 173 | 13 | 27 |
TissuGlu®
| |||
Mastectomy | 14 (44 %) | – | 7 (88 %) |
Axilla | 11 (34 %) | – | – |
SNL | 7 (22 %) | – | 1 (13 %) |
Total | 32 | – | 8 |
p
| 0.223 | >0.001 |